T-DM1 Extends Survival in HER2+ Breast Cancer

Cancer Discov. 2016 Feb;6(2):OF4. doi: 10.1158/2159-8290.CD-NB2015-174. Epub 2015 Dec 16.

Abstract

Results from the phase III TH3RESA study show that T-DM1 is effective in patients with metastatic HER2-positive breast cancer that has progressed despite two or more HER2-targeted therapies, extending their median overall survival by nearly 7 months.

Publication types

  • News

MeSH terms

  • Ado-Trastuzumab Emtansine
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics
  • Breast Neoplasms / mortality*
  • Clinical Trials, Phase III as Topic
  • Female
  • Humans
  • Maytansine / analogs & derivatives*
  • Maytansine / therapeutic use
  • Mutation
  • Receptor, ErbB-2 / genetics*
  • Survival Analysis
  • Trastuzumab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Maytansine
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab
  • Ado-Trastuzumab Emtansine